Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of “Moderate Buy” by Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $3.3333.

A number of equities analysts have commented on CGTX shares. B. Riley reissued a “buy” rating and issued a $3.00 price objective (up from $2.00) on shares of Cognition Therapeutics in a research note on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Cognition Therapeutics in a research report on Thursday, December 4th. Finally, Wall Street Zen upgraded Cognition Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp purchased a new position in shares of Cognition Therapeutics during the 3rd quarter worth about $25,000. Gamco Investors INC. ET AL bought a new stake in Cognition Therapeutics in the third quarter worth about $27,000. Private Management Group Inc. bought a new stake in Cognition Therapeutics in the third quarter worth about $32,000. CWA Asset Management Group LLC purchased a new position in shares of Cognition Therapeutics during the third quarter valued at approximately $34,000. Finally, Raymond James Financial Inc. grew its stake in shares of Cognition Therapeutics by 34.7% during the third quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after buying an additional 7,641 shares during the last quarter. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Stock Down 1.4%

Shares of CGTX stock opened at $1.41 on Friday. The company’s fifty day simple moving average is $1.56 and its two-hundred day simple moving average is $1.46. Cognition Therapeutics has a 52 week low of $0.22 and a 52 week high of $3.83. The stock has a market cap of $124.46 million, a P/E ratio of -2.94 and a beta of 1.26.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. On average, analysts anticipate that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.